MannKind | MNKD - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Adma Biologics USD 138.15M 50.52M 2026-03
BioCryst Pharmaceuticals USD 171.59M 164.32M 2026-03
Eli Lilly USD 5.28B 1.99B 2026-03
Halozyme Therapeutics USD 309.75M 175.93M 2026-03
Insmed USD 582.19M 71.74M 2026-03
Karyopharm Therapeutics USD 60.54M 22.87M 2025-12
MacroGenics USD 66.52M 9.3M 2026-03
MannKind USD 52.83M 22.05M 2026-03
Merck USD 5.33B 9.24B 2026-03
Minerva Neurosciences USD 82.3M 70.02M 2025-12
Novavax USD 228.36M 12.27M 2026-03
Novo Nordisk DKK 38.94B 24.15B 2025-03
Pfizer USD 1.7B 561M 2026-03
Sanofi EUR 7.66B 1.25B 2025-12
Xencor USD 14.17M 39.9M 2026-03